Clinical trial NCT02694770: A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD
Official title: A Phase II Study of Neihulizumab vs "Conventional Treatment" to Treat Steroid-refractory Acute Graft-vs-host Disease (Sr-aGvHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
Keywords: aGvHD
GvHD
sr-aGvHD
biologics
monoclonal antibody
Lead sponsor: AbGenomics B.V Taiwan Branch
Sponsor class: INDUSTRY
First posted: 2016-03-01
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to assess the efficacy of Neihulizumab versus "conventional therapy" and to evaluate safety, pharmacokinetics and immunogenicity in treating steroid-refractory acute Graft-vs-Host Disease

Detailed description: This current Phase II trial is a randomized, open label, controlled, multiple dose, multi-centre study to study the clinical efficacy and safety of Neihulizumab vs "Conventional Treatment" to treat steroid-refractory acute graft-vs-host disease (sr-aGvHD) in patients undergoing allogeneic hematopoietic cell transplantation.

This study will enroll a minimum of 90 patients, approximately 60 in Neihulizumab treatment arm and 30 in Conventional treatment control arm.

The primary objectives is to evaluate the efficacy of Neihulizumab treatment in patients with steroid-refractory acute GvHD compared to "conventional treatment." The secondary objectives are to investigate safety, pharmacokinetics, and immunogenicity of Neihulizumab administration in subjects with steroid-refractory acute GvHD.

For safety evaluation, the parameters to be assessed are adverse events (AEs), discontinuation of therapy due to AEs, safety laboratory analysis, ECG, vital signs, physical examination, and immunogenicity.

Eligibility criteria: Inclusion Criteria:

1. Patient must be ≥18years of age, males or females;
2. Patient must have been recipients of a single allogeneic HCT; bone marrow, peripheral blood and/or umbilical cord blood recipients are allowed
3. Patients must have aGvHD without feature of classic chronic GvHD or overlap GvHD;
4. Patients must have received no prior treatment for aGvHD other than steroids;
5. Patients must have biopsy proven grade II to IV aGvHD progressing after at least 3 days, non-improving grade III to IV aGvHD persistent after at least 7 days, or non-improving grade II aGvHD persistent after at least 14 days of methylprednisolone 2mg/kg/day or equivalent; Patients with initial response but have flare of aGvHD within 14 days with methylprednisolone \> 0.5 mg/kg/day or equivalent are also eligible;
6. Patient must have an ANC of \> 500/mm3 and no evidence of HCT graft failure or multi-organ failure;
7. Patient must have Karnofsky Performance Status (KPS) ≥50%;
8. Patient must give informed consent and sign an approved consent form prior to any study procedures;
9. Females of childbearing potential must have a negative pregnancy test result prior to enrollment. Males and females of childbearing potential must agree to use a highly effective method of birth control during the study.

Exclusion Criteria:

1. Uncontrolled infections not responsive to antimicrobial therapy or requiring intensive critical care or vasopressors;
2. Evidence of end-organ infection due to CMV;
3. HIV infection or a known HIV-related malignancy (NOTE: patients positive for hepatitis B or hepatitis C are not excluded, and may be evaluated on a case by case basis).
4. Tuberculosis, history of tuberculosis or a known positive Quantiferon test for tuberculosis
5. Donor lymphocyte infusion for residual or relapsed disease or mixed chimerism. DLI as part of the planned HCT protocol are allowed
6. Relapsed disease after transplant or progressive malignant disease, including post-transplant lymphoproliferative disease; any secondary malignancy diagnosed since HCT
7. Renal failure requiring hemodialysis
8. Need ICU care, with life expectancy of less than 28 days, with ongoing or unresolved veno-occlusive disease, with unstable hemodynamics, with evidence of current or previous clinically significant disease, medical condition or finding of the medical examination (including vital signs and ECG), that in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data
9. History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients
10. Pregnant or nursing

Primary outcomes:
measure: Overall response rate (Complete Response+Partial Response)
timeFrame: Day 28 after the initiation of sr-aGvHD treatment
Secondary outcomes:
measure: Overall response rate (Complete Response+Partial Response)
timeFrame: Day 56 after the initiation of sr-aGvHD treatment
measure: Complete Response+Very Good Partial Response
timeFrame: Day 28 and Day 56 after the initiation of sr-aGvHD treatment
measure: Overall survival
timeFrame: Day 180 after the initiation of sr-aGvHD treatment
measure: Cumulative steroid dose
timeFrame: Day 28 after the initiation of sr-aGvHD treatment
measure: Cumulative incidence of chronic GvHD
timeFrame: Day 180 after the initiation of sr-aGvHD treatment
measure: Cumulative incidence of primary disease relapse
timeFrame: Day 180 after the initiation of sr-aGvHD treatment
Other outcomes:
Locations:
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Research Center
state: Washington
Study officials:
affiliation: AbGenomics B.V.
name: Shih-Yao Lin, MD, PhD
role: STUDY_CHAIR
affiliation: Fred Hutchinson Cancer Center
name: Paul Martin (Lead), MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Fred Hutchinson Cancer Center
name: Marco Mielcarek (Co-Lead), MD
role: PRINCIPAL_INVESTIGATOR
affiliation: M.D. Anderson Cancer Center
name: Amin Alousi (Co-Lead), MD
role: PRINCIPAL_INVESTIGATOR
References: